Close Menu

This article has been updated with additional details on the coverage criteria of the LCD.

NEW YORK (GenomeWeb) – Genomic Health today announced that Medicare contractor Palmetto GBA has issued a draft local coverage determination for its Oncotype DX prostate cancer test.

The draft LCD recommends coverage of the test for qualified Medicare patients "to help determine which patients with early-stage, needle biopsy proven prostate cancer can be conservatively managed rather than treated with definitive surgery or radiation therapy."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.